A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.
about
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceTherapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemiaRegulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylasesCalcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation.Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Small-molecule inhibitors of signal transduction pathways in leukemia therapeutics: how to assess selectivity for malignant signals.JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation.Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment.Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesisContributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence.Emerging MEK inhibitors.Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation.Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.
P2860
Q24645668-1DDEACAF-310F-4163-A2C2-961EEA156AA3Q28354257-CDD9F2CC-15A9-4F0D-987F-0ABF0B6F760EQ30371492-AAF4E3C7-1188-40C7-BC1B-52782E87570AQ33938470-43F12EFC-19A9-4D21-928D-DDDDA2784889Q34099193-1F83F60A-C3E3-4905-9A24-998C5C624B92Q35166852-CEC2C24F-8A97-433D-84EE-58D079AB8455Q35186888-167A0C0C-4229-4156-A01D-4A7EFA05DB1CQ35217401-EE2B7E99-2175-44C1-A534-86CBFE52509BQ35635353-3DB0DAA6-9F2C-40BF-8AF9-D2E7999BE766Q35804128-600143F2-396A-4716-8E14-C87120F1EC0EQ35989404-1B57AA51-A972-4014-A5D3-89CECCE56A11Q37043876-82120CDC-2634-4B1B-B1B6-336BD19108FEQ37109227-B5FEEE67-9ACE-44BE-864B-1504B57569FCQ37620721-39DC0981-679C-4CF7-A6B3-FD2428DAA3B6Q37691441-BE2B47D9-F7DD-46D6-8E49-675A5CDDB752Q37822317-57D93F65-ECC0-4421-9320-AE906634CAD1Q37865381-A5600C16-C492-46A2-98AC-95E9D0AAFAB1Q39023984-DFA0C154-81D3-4AB6-AC60-27CA35851230Q39383689-1392E6BD-D1FF-4929-A2CB-501DF8F75DDBQ39732365-6B97D842-0151-47C3-93B8-99DEED6085D8Q40154931-33FAF167-9E19-4D87-AEC2-CC82460ACEAFQ40383692-E3EB970F-EEFD-4B87-B0E2-E50049BB46EEQ40516595-046F9B3C-3A94-4A25-B4C0-722D62CD40C0Q40594564-C6625F59-BABE-42D7-97E5-B76FC9281FF8Q40635020-8C4F65B7-B799-4043-ACF1-F016293DFBC6Q40752107-7A47A046-D489-4DFC-A69F-56806BF63FE3Q43819789-10A117CB-4EAE-4282-A1F9-08D710BE691FQ44452162-08F46520-86DB-45A0-B52C-4AEC44833C95Q47110143-F311687A-58C6-486A-BE52-442017C9DBC7
P2860
A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
A conditionally-active form of ...... and mouse hematopoietic cells.
@en
type
label
A conditionally-active form of ...... and mouse hematopoietic cells.
@en
prefLabel
A conditionally-active form of ...... and mouse hematopoietic cells.
@en
P2093
P2860
P356
P1433
P1476
A conditionally-active form of ...... and mouse hematopoietic cells
@en
P2093
H Cherwinski
J A McCubrey
L S Steelman
R A Franklin
S A McCarthy
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203337
P407
P577
2000-01-01T00:00:00Z
P5875
P6179
1037872122